A small team of Israeli scientists claim that they might have found the first complete cure for cancer.
“We believe we will offer in a year’s time a complete cure for cancer”
….said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator in the Weizmann Science Park.
AEBi developed the SoAP platform, which provides functional leads to very difficult targets. Aridor added,
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.”
What you must know – Cancer is an abnormal growth of cells
- There are more than 100 types, including skin cancer, lung cancer, breast cancer and colon cancer, and the disease is the second leading cause of death in the United States
- As reported by International Agency for Research on Cancer, an estimated 18.1 million new cancer cases are diagnosed worldwide each year
- Every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease)
ALSO READ –
About the Drug – ‘MuTaTo’ (multi-target toxin)
- The game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies
- It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage, a virus that infects bacteria
- That protein is then displayed on the surface of the phage
- As per the Israeli doctors, their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic which will be a disruption technology of the highest order
- Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules
- In contrast, MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically
Dr. Ilan Morad, who works with Aridor, is hopeful of Aebi’s method.
“We make sure that the treatment is not affected by the mutations; the cancer cells can mutate in such a way that the cancer discards the targeted receptors.”
“The probability of having multiple mutations that would modify all the targeted receptors decreases dramatically with the number of targets used,” Morad continued. “Instead of attacking the receivers one at a time, we attack the receivers three at a time; even cancer cannot mutate three receptors at the same time.”
The concept of MuTaTo has been equated to the triple drug cocktail that has helped change AIDS from being an automatic death sentence to a chronic but often manageable disease.
ALSO READ –